Gsa Capital Partners LLP Otonomy, Inc. Transaction History

Gsa Capital Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$1.22 - $2.2 $46,059 - $83,058	-37,754 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$2.06 - $2.67 $77,773 - $100,803	37,754 New	37,754 $84,000
Q1 2021 May 10, 2021	SELL	$2.49 - $6.23 $62,028 - $155,195	-24,911 Closed	0 $0
Q4 2020 Feb 03, 2021	SELL	$3.48 - $6.47 $185,574 - $345,019	-53,326 Reduced 68.16%	24,911 $161,000
Q3 2020 Nov 06, 2020	BUY	$3.16 - $4.36 $247,228 - $341,113	78,237 New	78,237 $317,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.